Schroth Johannes, Thiemermann Christoph, Henson Siân M
Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Front Cell Dev Biol. 2020 Oct 9;8:564461. doi: 10.3389/fcell.2020.564461. eCollection 2020.
Chronic kidney disease (CKD) presents an ever-growing disease burden for the world's aging population. It is characterized by numerous changes to the kidney, including a decrease in renal mass, renal fibrosis, and a diminished glomerular filtration rate. The premature aging phenotype observed in CKD is associated with cellular senescence, particularly of renal tubular epithelial cells (TECs), which contributes to chronic inflammation through the production of a proinflammatory senescence associated secretory phenotype (SASP). When coupled with changes in immune system composition and progressive immune dysfunction, the accumulation of senescent kidney cells acts as a driver for the progression of CKD. The targeting of senescent cells may well present an attractive therapeutic avenue for the treatment of CKD. We propose that the targeting of senescent cells either by direct inhibition of pro-survival pathways (senolytics) or through the inhibition of their proinflammatory secretory profile (senomorphics) together with immunomodulation to enhance immune system surveillance of senescent cells could be of benefit to patients with CKD.
慢性肾脏病(CKD)给全球老龄化人口带来了日益沉重的疾病负担。其特征是肾脏出现众多变化,包括肾实质减少、肾纤维化以及肾小球滤过率降低。在CKD中观察到的早衰表型与细胞衰老有关,尤其是肾小管上皮细胞(TECs)的衰老,这通过产生促炎衰老相关分泌表型(SASP)导致慢性炎症。当与免疫系统组成的变化和进行性免疫功能障碍相结合时,衰老肾细胞的积累成为CKD进展的驱动因素。靶向衰老细胞很可能为CKD的治疗提供一条有吸引力的治疗途径。我们提出,通过直接抑制促生存途径(衰老细胞溶解剂)或通过抑制其促炎分泌谱(衰老细胞形态调节剂)来靶向衰老细胞,同时进行免疫调节以增强免疫系统对衰老细胞的监测,可能对CKD患者有益。